ADReCS

Pharmaceutical Information

Drug Name	Losartan
Drug ID	BADD_D01322
Description	Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage	Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension.[L7423] Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).[L7426]
Marketing Status	approved
ATC Code	C09CA01
DrugBank ID	DB00678
KEGG ID	D08146
MeSH ID	D019808
PubChem ID	3961
TTD Drug ID	D0DD0K
NDC Product Code	70010-741; 62207-742; 70010-742; 70010-743
UNII	JMS50MPO89
Synonyms	Losartan \| 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol \| DuP-753 \| DuP 753 \| DuP753 \| MK-954 \| MK 954 \| MK954 \| Cozaar \| Losartan Potassium \| Potassium, Losartan \| Losartan Monopotassium Salt \| Monopotassium Salt, Losartan \| Salt, Losartan Monopotassium

Chemical Information

Molecular Formula	C22H23ClN6O
CAS Registry Number	114798-26-4
SMILES	CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Speech disorder	22.12.03.027; 17.02.08.003; 19.19.02.002	0.000050%		Not Available
Splenomegaly	01.09.02.001	0.000022%		Not Available
Squamous cell carcinoma of skin	23.08.02.005; 16.03.02.005	0.000010%		Not Available
Stevens-Johnson syndrome	10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005	-	-
Stress	19.06.02.004	0.000037%		Not Available
Subarachnoid haemorrhage	24.07.04.004; 17.08.01.010; 12.01.10.011	0.000020%		Not Available
Supraventricular tachycardia	02.03.03.012	0.000027%
Swelling	08.01.03.015	0.000146%		Not Available
Swelling face	08.01.03.100; 23.04.01.018; 10.01.05.018	0.000170%		Not Available
Swollen tongue	23.04.01.014; 10.01.05.015; 07.14.02.003	0.000157%		Not Available
Syncope	02.11.04.015; 24.06.02.012; 17.02.04.008	0.000210%
Systemic lupus erythematosus	23.03.02.006; 15.06.02.003; 10.04.03.004	0.000010%		Not Available
Tachycardia	02.03.02.007	0.000125%		Not Available
Tendon disorder	12.01.07.019; 15.07.01.002	0.000010%		Not Available
Tendonitis	15.07.01.003; 12.01.07.007	0.000020%		Not Available
Tension	19.06.02.005	-	-	Not Available
Therapeutic response unexpected	08.06.01.001	0.000077%		Not Available
Throat tightness	22.12.03.031; 19.01.02.005	0.000015%		Not Available
Thrombocytopenia	01.08.01.002	-	-	Not Available
Tinnitus	17.04.07.004; 04.04.01.002	0.000035%
Tongue disorder	07.14.01.002	0.000022%		Not Available
Toothache	07.09.06.001	0.000010%
Toxic epidermal necrolysis	10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006	-	-
Transient global amnesia	17.03.02.004; 19.20.01.004	0.000010%		Not Available
Transient ischaemic attack	24.04.06.005; 17.08.04.001	0.000025%
Transitional cell carcinoma	20.08.01.010; 16.08.04.002	0.000025%		Not Available
Transplant rejection	12.02.05.022; 10.02.03.002	0.000010%		Not Available
Tremor	17.01.06.002	0.000166%
Type I hypersensitivity	10.01.03.006	0.000025%		Not Available
Upper gastrointestinal haemorrhage	24.07.02.024; 07.12.02.006	0.000015%

The 11th Page First Pre 11 12 13 14 15 Next Last Total 16 Pages